Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2672 - Predictive and prognostic value of tumor cells and circulating plasma free DNA in advanced epithelial ovarian carcinoma


09 Sep 2017


Poster display session


Translational Research;  Ovarian Cancer


Jeronimo Martinez-Garcia


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


J. Martinez-Garcia1, A. Minguela Puras2, P.A. Cascales Campos3, M..V. Martinez Sanchez2, J. Gil Martinez3, F. Barcelo Valcarcel4, J.R. Rodriguez Hernandez4, M.A. Torroba Caron5, A. Soto-Gutierrez1, P. Sanchez Henarejos1, A. Puertes Boix1, S. Montenegro Luis1, P. Ruiz Carreño6, E. Rodriguez Braun7, M..D. Jimenez Lucas1, M. Guirao Marín1, M.A. Cuellar Rivas1, A. Cano Jimenez1, A. Anton Garcia8, J.L. Alonso Romero1

Author affiliations

  • 1 Medical Oncology, University Clinical Hospital Virgen de la Arrixaca, 30120 - Murcia/ES
  • 2 Immunoloy, University Clinical Hospital Virgen de la Arrixaca, 30120 - Murcia/ES
  • 3 Surgical Oncology, University Clinical Hospital Virgen de la Arrixaca, 30120 - Murcia/ES
  • 4 Gynaecology, University Clinical Hospital Virgen de la Arrixaca, 30120 - Murcia/ES
  • 5 Pathology, University Clinical Hospital Virgen de la Arrixaca, 30120 - Murcia/ES
  • 6 Nursing, University Clinical Hospital Virgen de la Arrixaca, 30120 - Murcia/ES
  • 7 Medical Oncology, University Hospital Santa Lucia, Cartagena/ES
  • 8 Genomic Deparment, Murcian Institute Biosanitary Research, Murcia/ES


Abstract 2672


In recent years there has been increasing interest in the study of circulating tumor cells (CTC) and plama cell-free circulating DNA (cfDNA) as a new biomarker in neoplastic diseases. Our work aims to clarify its clinical role in ovarian epithelial carcinoma (OEC).


A prospective, multicenter, observational study has been conducted for 3 years in patients with advanced or responsive OEC. The predictive value and prognosis of CTC and cfDNA have been determined for both progression-free survival (PFS) and overall survival (OS). Their values have been compared with a control group. CTC were analysed by the CellSearch method and cfDNA by ALU-sequences-based quantitative PCR using two primers (ALU115 and ALU247); cfDNA integrity was calculated by ALU247/ALU115 ratio. This study was approved by the Central Research Ethics Committee. Updated data are presented.


This study was conducted from November 2013 until December 2016. We recruited 88 patients, 15 benign tumors and 16 healthy subjects. Clinical characteristics were similar to other series, with a mean age of 57 years, 68.2% serous high grade subtype and 55.7% with stage IIIC. CTC were positive in 23.8% of patients (>1CTC/7,5mL). Levels of cfDNA were significantly elevated in patients than in the group of benign tumors and healthy control. CTC proved to be a negative prognostic factor of OS, with an average of 19.8 months versus 30.4 months (log-rank 4,649, p 


In summary, CTC and cfDNA in advanced ovarian epithelial carcinoma have been prognostic factors for survival. In addition, cfDNA has a predictive value of response. These two biomarkers may be useful in clinical practice.

Clinical trial identification

Legal entity responsible for the study

University Clinical Hospital Virgen Arrixaca - Murcia/ES




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.